Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Jan 1;97(1):232–237. doi: 10.1172/JCI118396

Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.

D T Eitzman 1, R D McCoy 1, X Zheng 1, W P Fay 1, T Shen 1, D Ginsburg 1, R H Simon 1
PMCID: PMC507084  PMID: 8550840

Abstract

Impaired fibrinolytic activity within the lung is a common manifestation of acute and chronic inflammatory lung diseases. Because the fibrinolytic system is active during repair processes that restore injured tissues to normal, reduced fibrinolytic activity may contribute to the subsequent development of pulmonary fibrosis. To examine the relationship between the fibrinolytic system and pulmonary fibrosis, lung inflammation was induced by bleomycin in transgenic mice that either overexpressed or were completely deficient in murine plasminogen activator inhibitor-1 (PAI-1). 2 wk after 0.075 U of bleomycin, the lungs of transgenic mice overexpressing PAI-1 contained significantly more hydroxyproline (118 +/- 8 micrograms) than littermate controls (70.5 +/- 8 micrograms, P < 0.005). 3 wk after administration of a higher dose of bleomycin (0.15 U), the lung hydroxyproline content of mice completely deficient in PAI-1 (49 +/- 8 micrograms) was not significantly different (P = 0.63) than that of control animals receiving saline (37 +/- 1 micrograms), while hydroxyproline content was significantly increased in heterozygote (77 +/- 12 micrograms, P = 0.06) and wild-type (124 +/- 19 micrograms, P < 0.001) littermates. These data demonstrate a direct correlation between the genetically determined level of PAI-1 expression and the extent of collagen accumulation that follows inflammatory lung injury. These results strongly support the hypothesis that alterations in fibrinolytic activity influence the extent of pulmonary fibrosis that occurs after inflammatory injury.

Full Text

The Full Text of this article is available as a PDF (602.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adamson I. Y., Bowden D. H. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol. 1974 Nov;77(2):185–197. [PMC free article] [PubMed] [Google Scholar]
  2. Bachofen M., Weibel E. R. Alterations of the gas exchange apparatus in adult respiratory insufficiency associated with septicemia. Am Rev Respir Dis. 1977 Oct;116(4):589–615. doi: 10.1164/arrd.1977.116.4.589. [DOI] [PubMed] [Google Scholar]
  3. Basset F., Ferrans V. J., Soler P., Takemura T., Fukuda Y., Crystal R. G. Intraluminal fibrosis in interstitial lung disorders. Am J Pathol. 1986 Mar;122(3):443–461. [PMC free article] [PubMed] [Google Scholar]
  4. Bertozzi P., Astedt B., Zenzius L., Lynch K., LeMaire F., Zapol W., Chapman H. A., Jr Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med. 1990 Mar 29;322(13):890–897. doi: 10.1056/NEJM199003293221304. [DOI] [PubMed] [Google Scholar]
  5. Burkhardt A. Alveolitis and collapse in the pathogenesis of pulmonary fibrosis. Am Rev Respir Dis. 1989 Aug;140(2):513–524. doi: 10.1164/ajrccm/140.2.513. [DOI] [PubMed] [Google Scholar]
  6. Carmeliet P., Kieckens L., Schoonjans L., Ream B., van Nuffelen A., Prendergast G., Cole M., Bronson R., Collen D., Mulligan R. C. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest. 1993 Dec;92(6):2746–2755. doi: 10.1172/JCI116892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., De Vos R., van den Oord J. J., Collen D., Mulligan R. C. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 1994 Mar 31;368(6470):419–424. doi: 10.1038/368419a0. [DOI] [PubMed] [Google Scholar]
  8. Carmeliet P., Stassen J. M., Schoonjans L., Ream B., van den Oord J. J., De Mol M., Mulligan R. C., Collen D. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest. 1993 Dec;92(6):2756–2760. doi: 10.1172/JCI116893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chapman H. A., Allen C. L., Stone O. L. Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am Rev Respir Dis. 1986 Mar;133(3):437–443. doi: 10.1164/arrd.1986.133.3.437. [DOI] [PubMed] [Google Scholar]
  10. Chapman H. A., Jr, Stone O. L. Co-operation between plasmin and elastase in elastin degradation by intact murine macrophages. Biochem J. 1984 Sep 15;222(3):721–728. doi: 10.1042/bj2220721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Crouch E. Pathobiology of pulmonary fibrosis. Am J Physiol. 1990 Oct;259(4 Pt 1):L159–L184. doi: 10.1152/ajplung.1990.259.4.L159. [DOI] [PubMed] [Google Scholar]
  12. Dang C. V., Bell W. R., Kaiser D., Wong A. Disorganization of cultured vascular endothelial cell monolayers by fibrinogen fragment D. Science. 1985 Mar 22;227(4693):1487–1490. doi: 10.1126/science.4038818. [DOI] [PubMed] [Google Scholar]
  13. Eitzman D. T., Fay W. P., Lawrence D. A., Francis-Chmura A. M., Shore J. D., Olson S. T., Ginsburg D. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest. 1995 May;95(5):2416–2420. doi: 10.1172/JCI117937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Erickson L. A., Fici G. J., Lund J. E., Boyle T. P., Polites H. G., Marotti K. R. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature. 1990 Jul 5;346(6279):74–76. doi: 10.1038/346074a0. [DOI] [PubMed] [Google Scholar]
  15. Fay W. P., Shapiro A. D., Shih J. L., Schleef R. R., Ginsburg D. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med. 1992 Dec 10;327(24):1729–1733. doi: 10.1056/NEJM199212103272406. [DOI] [PubMed] [Google Scholar]
  16. Gross T. J., Simon R. H., Kelly C. J., Sitrin R. G. Rat alveolar epithelial cells concomitantly express plasminogen activator inhibitor-1 and urokinase. Am J Physiol. 1991 Apr;260(4 Pt 1):L286–L295. doi: 10.1152/ajplung.1991.260.4.L286. [DOI] [PubMed] [Google Scholar]
  17. Hamsten A., Wiman B., de Faire U., Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985 Dec 19;313(25):1557–1563. doi: 10.1056/NEJM198512193132501. [DOI] [PubMed] [Google Scholar]
  18. Hart D. A., Whidden P., Green F., Henkin J., Woods D. E. Partial reversal of established bleomycin-induced pulmonary fibrosis by rh-urokinase in a rat model. Clin Invest Med. 1994 Apr;17(2):69–76. [PubMed] [Google Scholar]
  19. Hasday J. D., Bachwich P. R., Lynch J. P., 3rd, Sitrin R. G. Procoagulant and plasminogen activator activities of bronchoalveolar fluid in patients with pulmonary sarcoidosis. Exp Lung Res. 1988;14(2):261–278. doi: 10.3109/01902148809115128. [DOI] [PubMed] [Google Scholar]
  20. Idell S., Gonzalez K. K., MacArthur C. K., Gillies C., Walsh P. N., McLarty J., Thrall R. S. Bronchoalveolar lavage procoagulant activity in bleomycin-induced lung injury in marmosets. Characterization and relationship to fibrin deposition and fibrosis. Am Rev Respir Dis. 1987 Jul;136(1):124–133. doi: 10.1164/ajrccm/136.1.124. [DOI] [PubMed] [Google Scholar]
  21. Idell S., James K. K., Coalson J. J. Fibrinolytic activity in bronchoalveolar lavage of baboons with diffuse alveolar damage: trends in two forms of lung injury. Crit Care Med. 1992 Oct;20(10):1431–1440. doi: 10.1097/00003246-199210000-00012. [DOI] [PubMed] [Google Scholar]
  22. Idell S., James K. K., Gillies C., Fair D. S., Thrall R. S. Abnormalities of pathways of fibrin turnover in lung lavage of rats with oleic acid and bleomycin-induced lung injury support alveolar fibrin deposition. Am J Pathol. 1989 Aug;135(2):387–399. [PMC free article] [PubMed] [Google Scholar]
  23. Idell S., James K. K., Levin E. G., Schwartz B. S., Manchanda N., Maunder R. J., Martin T. R., McLarty J., Fair D. S. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest. 1989 Aug;84(2):695–705. doi: 10.1172/JCI114217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Idell S., Peters J., James K. K., Fair D. S., Coalson J. J. Local abnormalities of coagulation and fibrinolytic pathways that promote alveolar fibrin deposition in the lungs of baboons with diffuse alveolar damage. J Clin Invest. 1989 Jul;84(1):181–193. doi: 10.1172/JCI114139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kirchheimer J. C., Remold H. G. Endogenous receptor-bound urokinase mediates tissue invasion of human monocytes. J Immunol. 1989 Oct 15;143(8):2634–2639. [PubMed] [Google Scholar]
  26. Kuhn C., 3rd, Boldt J., King T. E., Jr, Crouch E., Vartio T., McDonald J. A. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis. 1989 Dec;140(6):1693–1703. doi: 10.1164/ajrccm/140.6.1693. [DOI] [PubMed] [Google Scholar]
  27. Laiho M., Keski-Oja J. Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res. 1989 May 15;49(10):2533–2553. [PubMed] [Google Scholar]
  28. Liotta L. A., Goldfarb R. H., Brundage R., Siegal G. P., Terranova V., Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 1981 Nov;41(11 Pt 1):4629–4636. [PubMed] [Google Scholar]
  29. Loskutoff D. J., Sawdey M., Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb. 1989;9:87–115. [PubMed] [Google Scholar]
  30. Marshall B. C., Brown B. R., Rothstein M. A., Rao N. V., Hoidal J. R., Rodgers G. M. Alveolar epithelial cells express both plasminogen activator and tissue factor. Potential role in repair of lung injury. Chest. 1991 Mar;99(3 Suppl):25S–27S. [PubMed] [Google Scholar]
  31. Miller S. A., Dykes D. D., Polesky H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988 Feb 11;16(3):1215–1215. doi: 10.1093/nar/16.3.1215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Mochan E., Keler T. Plasmin degradation of cartilage proteoglycan. Biochim Biophys Acta. 1984 Aug 21;800(3):312–315. doi: 10.1016/0304-4165(84)90412-4. [DOI] [PubMed] [Google Scholar]
  33. Peyrol S., Cordier J. F., Grimaud J. A. Intra-alveolar fibrosis of idiopathic bronchiolitis obliterans-organizing pneumonia. Cell-matrix patterns. Am J Pathol. 1990 Jul;137(1):155–170. [PMC free article] [PubMed] [Google Scholar]
  34. Phan S. H., Thrall R. S., Williams C. Bleomycin-induced pulmonary fibrosis. Effects of steroid on lung collagen metabolism. Am Rev Respir Dis. 1981 Oct;124(4):428–434. doi: 10.1164/arrd.1981.124.4.428. [DOI] [PubMed] [Google Scholar]
  35. Schrier D. J., Phan S. H., McGarry B. M. The effects of the nude (nu/nu) mutation on bleomycin-induced pulmonary fibrosis. A biochemical evaluation. Am Rev Respir Dis. 1983 May;127(5):614–617. doi: 10.1164/arrd.1983.127.5.614. [DOI] [PubMed] [Google Scholar]
  36. Senior R. M., Skogen W. F., Griffin G. L., Wilner G. D. Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. J Clin Invest. 1986 Mar;77(3):1014–1019. doi: 10.1172/JCI112353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Shen A. S., Haslett C., Feldsien D. C., Henson P. M., Cherniack R. M. The intensity of chronic lung inflammation and fibrosis after bleomycin is directly related to the severity of acute injury. Am Rev Respir Dis. 1988 Mar;137(3):564–571. doi: 10.1164/ajrccm/137.3.564. [DOI] [PubMed] [Google Scholar]
  38. Thrall R. S., Phan S. H., McCormick J. R., Ward P. A. The development of bleomycin-induced pulmonary fibrosis in neutrophil-depleted and complement-depleted rats. Am J Pathol. 1981 Oct;105(1):76–81. [PMC free article] [PubMed] [Google Scholar]
  39. Viscardi R. M., Broderick K., Sun C. C., Yale-Loehr A. J., Hessamfar A., Taciak V., Burke K. C., Koenig K. B., Idell S. Disordered pathways of fibrin turnover in lung lavage of premature infants with respiratory distress syndrome. Am Rev Respir Dis. 1992 Aug;146(2):492–499. doi: 10.1164/ajrccm/146.2.492. [DOI] [PubMed] [Google Scholar]
  40. WOESSNER J. F., Jr The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys. 1961 May;93:440–447. doi: 10.1016/0003-9861(61)90291-0. [DOI] [PubMed] [Google Scholar]
  41. Werb Z., Mainardi C. L., Vater C. A., Harris E. D., Jr Endogenous activiation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med. 1977 May 5;296(18):1017–1023. doi: 10.1056/NEJM197705052961801. [DOI] [PubMed] [Google Scholar]
  42. Wiman B., Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost. 1990 Jul;16(3):207–216. doi: 10.1055/s-2007-1002671. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES